Over 60 minutes participants using the 16mg EC
experienced significantly less craving than when
using the placebo EC (mean difference 0.82; 95% C.I.
0.25–1.38; p=0.0061). Cigarette use reduced craving
more than the 16mg (difference 1.44; 95% CI 0.39 to
2.48) and 0mg (difference 2.23; 95% CI 1.17 to 3.30).
ECs and Nicorette® inhalator (difference 1.54 95%
CI 0.48 to 2.59) over the same period.
Compared to the 0mg EC and Nicorette® inhalator, the 16mg
EC rated lowest for irritability, restlessness, poor
concentration and need for a cigarette but these
differences were not significant. The EC was well-
tolerated, acceptable and had fewer adverse effects
than the inhalator. The 16mg EC delivered nicotine
more rapidly (mean tmax 19.4 minutes) than
Nicorette® inhalator (30 minutes) but not as rapidly
as cigarettes (14.3 min), which also gave the highest
cmax of nicotine (13.4 ng/ml), almost ten-fold that of
the 16mg EC (0.9 ng/ml), and Nicorette® inhalator
(1.8 ng/ml).
Bookmarks